Q-omics provides the consensus-scored DDX39B profile across patient tissues and cancer cell-line models. DDX39B expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, DDX39B is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, DDX39B protein abundance shows 23,944 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight COAD, KIRC, and GBM as cancer lineages where DDX39B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DDX39B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DDX39B survival associations across molecular data types. DDX39B RNA expression shows survival associations in the most cancer types (28), followed by mutation status (7) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DDX39B RNA expression–survival associations across cancer types. High DDX39B expression shows unfavorable associations in COAD, ACC, KIRC and LIHC, but favorable associations in BLCA and READ. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for DDX39B RNA expression.
This table summarizes DDX39B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for DDX39B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DDX39B shows higher tumor expression in KIRC, HNSC, COAD, LIHC, CHOL and BLCA. The KIRC box plot shows higher DDX39B RNA expression in tumor versus normal tissue (log2 FC = +0.802, t-test p < 0.001).
This table shows molecular features associated with DDX39B in patient tissues and cancer cell lines. In patient samples, DDX39B shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, DDX39B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and SOFT_TISSUE.
